Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multi-center, Dose-escalation Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of ISU304 in Previously Treated Hemophilia B Patients

NCT03186677 is registered in ClinicalTrials.gov with ISU Abxis Co., Ltd. as lead sponsor.

NCT NCT03186677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03186677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multi-center, Dose-escalation Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of ISU304 in Previously Treated Hemophilia B Patients
Lead sponsor
ISU Abxis Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 3, 2017
Completion date
February 22, 2019
Enrollment
11 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b